<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">NCP</journal-id>
<journal-id journal-id-type="hwp">spncp</journal-id>
<journal-id journal-id-type="nlm-ta">Nutr Clin Pract</journal-id>
<journal-title>Nutrition in Clinical Practice</journal-title>
<issn pub-type="ppub">0884-5336</issn>
<issn pub-type="epub">1941-2452</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0884533611436115</article-id>
<article-id pub-id-type="publisher-id">10.1177_0884533611436115</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Clinical Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A Double-Blind Randomized Study Comparing the Efficacy and Safety of a Composite vs a Conventional Intravenous Fat Emulsion in Postsurgical Gastrointestinal Tumor Patients</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Ma</surname><given-names>Cheng-Jen</given-names></name>
<xref ref-type="aff" rid="aff1-0884533611436115">1</xref>
<xref ref-type="aff" rid="aff2-0884533611436115">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sun</surname><given-names>Li-Chu</given-names></name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff2-0884533611436115">2</xref>
<xref ref-type="aff" rid="aff3-0884533611436115">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname><given-names>Fang-Ming</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0884533611436115">1</xref>
<xref ref-type="aff" rid="aff2-0884533611436115">2</xref>
<xref ref-type="aff" rid="aff4-0884533611436115">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lu</surname><given-names>Chien-Yu</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0884533611436115">2</xref>
<xref ref-type="aff" rid="aff5-0884533611436115">5</xref>
<xref ref-type="aff" rid="aff6-0884533611436115">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shih</surname><given-names>Ying-Ling</given-names></name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="aff2-0884533611436115">2</xref>
<xref ref-type="aff" rid="aff3-0884533611436115">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tsai</surname><given-names>Hsiang-Lin</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff7-0884533611436115">7</xref>
<xref ref-type="aff" rid="aff11-0884533611436115">11</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chuang</surname><given-names>Jui-Fen</given-names></name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff2-0884533611436115">2</xref>
<xref ref-type="aff" rid="aff8-0884533611436115">8</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Wang</surname><given-names>Jaw-Yuan</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0884533611436115">1</xref>
<xref ref-type="aff" rid="aff2-0884533611436115">2</xref>
<xref ref-type="aff" rid="aff4-0884533611436115">4</xref>
<xref ref-type="aff" rid="aff9-0884533611436115">9</xref>
<xref ref-type="aff" rid="aff10-0884533611436115">10</xref>
</contrib>
<aff id="aff1-0884533611436115"><label>1</label>Division of Gastrointestinal and General Surgery, Department of Surgery</aff>
<aff id="aff2-0884533611436115"><label>2</label>Nutrition Support Team</aff>
<aff id="aff3-0884533611436115"><label>3</label>Department of Nursing</aff>
<aff id="aff4-0884533611436115"><label>4</label>Department of Surgery, Faculty of Medicine, College of Medicine</aff>
<aff id="aff5-0884533611436115"><label>5</label>Division of Gastroenterology, Department of Internal Medicine</aff>
<aff id="aff6-0884533611436115"><label>6</label>Department of Internal Medicine, College of Medicine</aff>
<aff id="aff7-0884533611436115"><label>7</label>Division of General Medicine Surgery, Department of Surgery</aff>
<aff id="aff8-0884533611436115"><label>8</label>Department of Pharmacy</aff>
<aff id="aff9-0884533611436115"><label>9</label>Cancer Center</aff>
<aff id="aff10-0884533611436115"><label>10</label>Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan</aff>
<aff id="aff11-0884533611436115"><label>11</label>School of Medical and Health Sciences, Fooyin University, Kaohsiung, Taiwan</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0884533611436115">Jaw-Yuan Wang, MD, PhD, Department of Surgery, Kaohsiung Medical University Hospital, 100 Tzyou 1st Rd, Kaohsiung 807, Taiwan; e-mail: <email>cy614112@ms14.hinet.net</email>; <email>jayuwa@cc.kmu.edu.tw</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>3</issue>
<issue-title>Cardiovascular and Critical Illness</issue-title>
<fpage>410</fpage>
<lpage>415</lpage>
<permissions>
<copyright-statement>© 2012 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p><italic>Background</italic>: Composite intravenous fat emulsion, a fat emulsion composed of soybean oil, medium-chain triglycerides (MCT), olive oil, and fish oil, was evaluated for metabolic efficacy, immune modulation, clinical efficacy, safety, and tolerance in surgical gastrointestinal (GI) tumor patients. <italic>Methods</italic>: In a prospective, randomized, double-blind study, 40 patients were randomized after elective digestive surgery to receive isonitrogenous, isoenergetic parenteral nutrition for 5 days postoperatively with either composite 20% IVFE (composed of soybean, MCT, olive, and fish oils) or a conventional long-chain triglyceride (LCT)/MCT 20% IVFE (LCT/MCT IVFE); IVFE was dosed at 1-2 g/kg body weight. Safety and efficacy parameters were assessed on operation day (day 0) and at the end of study (day 6). Adverse events were documented daily and clinical outcomes were recorded and compared between the groups. <italic>Results</italic>: Metabolic parameters, laboratory parameters, proinflammatory cytokine levels, adverse events, and clinical outcomes did not differ between the 2 groups, with the exception that postoperative low-density lipoprotein levels decreased significantly in the composite IVFE group (93.2 ± 24.3 vs 110.5 ± 26.4 mg/dL, <italic>P</italic> = .038). <italic>Conclusions</italic>: composite IVFE was comparable with conventional LCT/MCT IVFE in efficacy, safety, tolerance, and clinical outcomes in surgical GI tumor patients.</p>
</abstract>
<kwd-group>
<kwd>fat emulsions, intravenous</kwd>
<kwd>parenteral nutrition</kwd>
<kwd>fatty acids, omega-3</kwd>
<kwd>gastrointestinal neoplasms</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Lipids provide valuable sources for energy and essential fatty acids that constitute cell membranes. Diets with enriched ω-3 fatty acids have been demonstrated to modulate lipid profiles, which improves the outcome of hypertension<sup><xref ref-type="bibr" rid="bibr1-0884533611436115">1</xref><xref ref-type="bibr" rid="bibr2-0884533611436115"/>-<xref ref-type="bibr" rid="bibr3-0884533611436115">3</xref></sup> and coronary disease and decreases the risk of cardiovascular disease.<sup><xref ref-type="bibr" rid="bibr4-0884533611436115">4</xref><xref ref-type="bibr" rid="bibr5-0884533611436115"/>-<xref ref-type="bibr" rid="bibr6-0884533611436115">6</xref></sup> In addition, ω-3 fatty acids compete with ω-6 fatty lipids, which produce leukotrienes (LT), thromboxanes, and prostaglandins, and influence gene induction and cytokine release, culminating in inflammation. The anti-inflammatory and immunomodulatory potential of ω-3 fatty acids provides clinical benefits to immunologic diseases such as rheumatoid arthritis,<sup><xref ref-type="bibr" rid="bibr3-0884533611436115">3</xref>,<xref ref-type="bibr" rid="bibr7-0884533611436115">7</xref><xref ref-type="bibr" rid="bibr8-0884533611436115"/>-<xref ref-type="bibr" rid="bibr9-0884533611436115">9</xref></sup> lupus,<sup><xref ref-type="bibr" rid="bibr10-0884533611436115">10</xref>,<xref ref-type="bibr" rid="bibr11-0884533611436115">11</xref></sup> and inflammatory bowel disease,<sup><xref ref-type="bibr" rid="bibr12-0884533611436115">12</xref><xref ref-type="bibr" rid="bibr13-0884533611436115"/>-<xref ref-type="bibr" rid="bibr14-0884533611436115">14</xref></sup> as well as to immunocompromised situations, such as burns, trauma, sepsis, and systemic inflammatory response syndrome.<sup><xref ref-type="bibr" rid="bibr15-0884533611436115">15</xref><xref ref-type="bibr" rid="bibr16-0884533611436115"/>-<xref ref-type="bibr" rid="bibr17-0884533611436115">17</xref></sup> According to the literature, a balanced ω-6/ω-3 ratio ranging from 2:1 to 4:1 is most favorable, and fat emulsions composed of reduced long-chain triglycerides (LCT), replaced by medium-chain triglycerides (MCT), monounsaturated fatty acids (MUFA), and long-chain ω-3 fatty acids are recommended.<sup><xref ref-type="bibr" rid="bibr18-0884533611436115">18</xref><xref ref-type="bibr" rid="bibr19-0884533611436115"/>-<xref ref-type="bibr" rid="bibr20-0884533611436115">20</xref></sup></p>
<p>Depending on the type of surgery and the clinical course, enteral nutrition (EN) may be contraindicated for patients undergoing digestive surgery. Parenteral supply is a viable alternate for postoperative nutrition supplementation in these patients. Consequently, concerns arise regarding safety, tolerance, and metabolism, along with the clinical outcome of providing intravenous fat emulsion (IVFE). A number of studies regarding the administration of ω-3 IVFE have been published, but the results are inconsistent.</p>
<p>In the present study, a composite IVFE (SMOFlipid 20%, Fresenius Kabi, Bad Homburg, Germany) composed of soybean oil (LCT), MCT, olive oil (MUFA), and fish oil (long-chain ω-3 fatty acids), was compared with a conventional MCT/LCT IVFE (Lipovenoes MCT 20%, Fresenius Kabi, Bad Homburg, Germany) for postoperative parenteral nutrition (PN) in patients with gastrointestinal (GI) tumors following digestive surgery. We hypothesized that the ω-3 fatty acid–enriched composite IVFE could augment immunomodulatory and anti-inflammatory effects and subsequently improve clinical outcomes.</p>
<sec id="section1-0884533611436115" sec-type="methods">
<title>Patients and Methods</title>
<sec id="section2-0884533611436115">
<title>Patients</title>
<p>In this prospective randomized, double-blind study, 40 patients were recruited following elective digestive surgery in Kaohsiung Medical University Hospital. Equal numbers of patients were randomly assigned to 1 of 2 groups according to a randomization list, and then patients were registered in the subject enrollment log. Fat emulsion in the same packing was marked with the patient number. Excluded patients included those who had severe hypoalbuminemia (serum albumin level &lt;2.5 g/dL), diabetes mellitus, or hyperlipidemia (fasting serum triglyceride level &gt;250 mg/dL); were overweight (body mass index &gt;30 kg/m<sup>2</sup>); had abused drugs or had chronic alcoholism; had liver disease (serum total bilirubin level &gt;2 mg/dL), renal disease (serum creatinine level &gt;2 mg/dL or needing hemodialysis), heart failure, or life-threatening disease; were pregnant or lactating; had received chemotherapy within 14 days before the start of the trial; had already accepted EN; had participated in another clinical study with an investigational drug or an investigational medical device within a month prior to the start or during the study; and were hypersensitive to fish, egg, soy, or peanut protein. The protocol was approved by the local ethics committees and was carried out in accordance with the Declaration of Helsinki of 1975, as revised in 1996. Written informed consent of patients was obtained before the study was conducted.</p>
</sec>
<sec id="section3-0884533611436115">
<title>PN</title>
<p>Isoenergetic (30 kcal/kg body weight [BW]/d) PN, including 1.5 g/kg BW/d amino acid, 3-4 g/kg BW/d glucose, 1-2 g/kg BW/d lipid, and electrolytes, microelements, and vitamins that depended on the patients’ condition and followed the standard procedure of the hospital, was infused continuously daily for 24 hours. Either composite IVFE or LCT/MCT IVFE was randomly administered separately in accordance with the assignment of patients for consecutive 5 days after surgery. Both IVFEs were infused constantly for 8 hours. The composition of each IVFE is shown in <xref ref-type="table" rid="table1-0884533611436115">Table 1</xref>. Enteral intake was restricted to clear liquid during 5 days postoperatively.</p>
<table-wrap id="table1-0884533611436115" position="float">
<label>Table 1.</label>
<caption>
<p>Composition of Composite 20% IVFE and LCT/MCT IVFE 20%</p>
</caption>
<graphic alternate-form-of="table1-0884533611436115" xlink:href="10.1177_0884533611436115-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Composite IVFE</th>
<th align="center">LCT/MCT IVFE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soybean oil, g/L</td>
<td>60</td>
<td>100</td>
</tr>
<tr>
<td>MCT, g/L</td>
<td>60</td>
<td>100</td>
</tr>
<tr>
<td>Olive oil, g/L</td>
<td>50</td>
<td>—</td>
</tr>
<tr>
<td>Fish oil, g/L</td>
<td>30</td>
<td>—</td>
</tr>
<tr>
<td>ω-6/ω-3 fatty acid ratio</td>
<td>2.5:1</td>
<td>7:1</td>
</tr>
<tr>
<td>Egg phospholipids, g/L</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Glycerol, g/L</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td>All-rac-α-tocopherol, mg/L</td>
<td>200</td>
<td>—</td>
</tr>
<tr>
<td>Total energy, kcal/L</td>
<td>2000</td>
<td>1950</td>
</tr>
<tr>
<td>pH</td>
<td>~8</td>
<td>6.5–8.7</td>
</tr>
<tr>
<td>Osmolarity, mOsm/L</td>
<td>290</td>
<td>273</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0884533611436115">
<p>MCT, medium-chain triglycerides.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section4-0884533611436115">
<title>Assessment of Efficacy, Safety, and Tolerance</title>
<p>Vital signs, fluid input, clinical course, concomitant medication, concomitant procedure, and adverse events were recorded daily between the operation day (day 0) and end of study (day 6). Blood samples, urine, and body weight were obtained and documented on day 0 and day 6. Metabolic efficacy was measured by serum levels of glucose, triglyceride, albumin, prealbumin, and cholesterol (including total, high-density lipoprotein [HDL], and low-density lipoprotein [LDL]). Nitrogen balance and body mass index were also calculated. The inflammation-related cytokines, including interleukin (IL)–1β, IL-6, and tumor necrosis factor–α (TNF-α), were determined by enzyme-linked immunosorbent assay (Quantikine; R&amp;D Systems, Minneapolis, MN), and C-reactive protein (CRP) was also measured. Clinical efficacy was evaluated on the basis of postoperative complications and length of postoperative hospital stay (LOS). Laboratory data, including hematology, serum levels of urea nitrogen, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin, were recorded. Any adverse event was documented daily, with the study being terminated if serious adverse events developed.</p>
</sec>
<sec id="section5-0884533611436115">
<title>Statistical Analysis</title>
<p>All data were statistically analyzed using the Statistical Package for the Social Sciences, version 17.0 (SPSS, Inc, an IBM Company, Chicago, IL). Nominal data were tested with either χ<sup>2</sup> or Fisher exact test as appropriate. Laboratory parameters before administration of PN demonstrated no statistical differences between the study groups, and thus these values were regarded as baseline. Statistical analyses were then performed using an independent Student <italic>t</italic> test, with values expressed as mean ± SD. A <italic>P</italic> value of less than .05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="section6-0884533611436115" sec-type="results">
<title>Results</title>
<p>The patient characteristics are listed in <xref ref-type="table" rid="table2-0884533611436115">Table 2</xref>. The groups were comparable with respect to demographic data and diagnosed diseases. No difference was found in fluid input, concomitant medications, or concomitant procedures between the test groups. No significant differences were found in nutrition parameters between the 2 groups, except for LDL, which was decreased significantly in the composite IVFE group as compared with the LCT/MCT IVFE group (<xref ref-type="table" rid="table3-0884533611436115">Table 3</xref>). The total cholesterol level decreased slightly in the composite IVFE group, and the triglyceride level increased in both groups after infusion, but the changes were not statistically significant (both <italic>P &gt;</italic> .05).</p>
<table-wrap id="table2-0884533611436115" position="float">
<label>Table 2.</label>
<caption>
<p>Demographic Data for the Patient Groups</p>
</caption>
<graphic alternate-form-of="table2-0884533611436115" xlink:href="10.1177_0884533611436115-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">composite IVFE (n = 20)</th>
<th align="center">LCT/MCT IVFE (n = 20)</th>
<th align="center"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, male/female, No.</td>
<td>10/10</td>
<td>10/10</td>
<td>1.000</td>
</tr>
<tr>
<td>Age, y, mean ± SD</td>
<td>67.7 ± 10.9</td>
<td>63.2 ± 13.4</td>
<td>.256</td>
</tr>
<tr>
<td>Diagnosis, No.</td>
<td/>
<td/>
<td>.320</td>
</tr>
<tr>
<td> Colon cancer</td>
<td>12</td>
<td>17</td>
<td/>
</tr>
<tr>
<td> Gastric cancer</td>
<td>3</td>
<td>1</td>
<td/>
</tr>
<tr>
<td> GIST</td>
<td>1</td>
<td>0</td>
<td/>
</tr>
<tr>
<td> Colon polyp</td>
<td>3</td>
<td>1</td>
<td/>
</tr>
<tr>
<td> Gastric polyp</td>
<td>1</td>
<td>0</td>
<td/>
</tr>
<tr>
<td> Duodenal polyp</td>
<td>0</td>
<td>1</td>
<td/>
</tr>
<tr>
<td>UICC stage, No.</td>
<td/>
<td/>
<td>.305</td>
</tr>
<tr>
<td> Stage I</td>
<td>2</td>
<td>3</td>
<td/>
</tr>
<tr>
<td> Stage II</td>
<td>7</td>
<td>6</td>
<td/>
</tr>
<tr>
<td> Stage III</td>
<td>3</td>
<td>8</td>
<td/>
</tr>
<tr>
<td> Stage IV</td>
<td>3</td>
<td>1</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0884533611436115">
<p><italic>Note</italic>.5 benign diagnoses in the composite IVFE group and 2 benign diagnoses in the LCT/MCT IVFE group were not counted in the UICC stage. GIST, gastrointestinal stromal tumor; MCT, medium-chain triglycerides; UICC, Union of International Cancer Control.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-0884533611436115" position="float">
<label>Table 3.</label>
<caption>
<p>Various Nutrition Parameters of the Study Groups Before and After Surgery</p>
</caption>
<graphic alternate-form-of="table3-0884533611436115" xlink:href="10.1177_0884533611436115-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Day 0</th>
<th align="center">Day 6</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn4-0884533611436115">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cholesterol, mg/dL</td>
<td/>
<td/>
<td>.118</td>
</tr>
<tr>
<td> Composite IVFE</td>
<td>167.9 ± 26.7</td>
<td>154.8 ± 35.9</td>
<td/>
</tr>
<tr>
<td> LCT/MCT IVFE</td>
<td>169.7 ± 28.6</td>
<td>170.6 ± 25.2</td>
<td/>
</tr>
<tr>
<td>HDL, mg/dL</td>
<td/>
<td/>
<td>.245</td>
</tr>
<tr>
<td> Composite IVFE</td>
<td>34.5 ± 8.8</td>
<td>22.0 ± 8.4</td>
<td/>
</tr>
<tr>
<td> LCT/MCT IVFE</td>
<td>36.2 ± 17.0</td>
<td>25.2 ± 8.8</td>
<td/>
</tr>
<tr>
<td>LDL, mg/dL</td>
<td/>
<td/>
<td>.038</td>
</tr>
<tr>
<td> Composite IVFE</td>
<td>106.2 ± 22.7</td>
<td>93.2 ± 24.3</td>
<td/>
</tr>
<tr>
<td> LCT/MCT IVFE</td>
<td>108.9 ± 30.6</td>
<td>110.5 ± 26.4</td>
<td/>
</tr>
<tr>
<td>Triglycerides, mg/dL</td>
<td/>
<td/>
<td>.349</td>
</tr>
<tr>
<td> Composite IVFE</td>
<td>103.0 ± 32.7</td>
<td>140.0 ± 59.9</td>
<td/>
</tr>
<tr>
<td> LCT/MCT IVFE</td>
<td>92.4 ± 39.8</td>
<td>158.3 ± 62.4</td>
<td/>
</tr>
<tr>
<td>Prealbumin, mg/dL</td>
<td/>
<td/>
<td>.100</td>
</tr>
<tr>
<td> Composite IVFE</td>
<td>19.11 ± 6.4</td>
<td>18.4 ± 6.5</td>
<td/>
</tr>
<tr>
<td> LCT/MCT IVFE</td>
<td>17.5 ± 6.3</td>
<td>21.7 ± 5.9</td>
<td/>
</tr>
<tr>
<td>Albumin, g/dL</td>
<td/>
<td/>
<td>.140</td>
</tr>
<tr>
<td> Composite IVFE</td>
<td>3.8 ± 0.4</td>
<td>3.5 ± 0.4</td>
<td/>
</tr>
<tr>
<td> LCT/MCT IVFE</td>
<td>3.8 ± 0.5</td>
<td>3.7 ± 0.4</td>
<td/>
</tr>
<tr>
<td>Transferrin, mg/dL</td>
<td/>
<td/>
<td>.380</td>
</tr>
<tr>
<td> Composite IVFE</td>
<td>222.6 ± 43.2</td>
<td>202.6 ± 40.4</td>
<td/>
</tr>
<tr>
<td> LCT/MCT IVFE</td>
<td>221.2 ±47.8</td>
<td>214.8 ± 45.0</td>
<td/>
</tr>
<tr>
<td>Nitrogen balance, g/d</td>
<td/>
<td/>
<td>.776</td>
</tr>
<tr>
<td> Composite IVFE</td>
<td>−6.0 ± 3.1</td>
<td>2.6 ± 3.6</td>
<td/>
</tr>
<tr>
<td> LCT/MCT IVFE</td>
<td>−6.1 ± 2.9</td>
<td>2.9 ± 2.6</td>
<td/>
</tr>
<tr>
<td>BMI, kg/m<sup>2</sup></td>
<td/>
<td/>
<td>.107</td>
</tr>
<tr>
<td> Composite IVFE</td>
<td>24.1 ± 3.5</td>
<td>23.4 ± 3.6</td>
<td/>
</tr>
<tr>
<td> LCT/MCT IVFE</td>
<td>22.5 ± 2.4</td>
<td>21.8 ± 2.3</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0884533611436115">
<p>BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MCT, medium-chain triglycerides.</p>
</fn>
<fn id="table-fn4-0884533611436115">
<label>a</label>
<p>The difference between the 2 groups at postoperative time points (day 6).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The postoperative hematological and biochemical data were similar in the study groups (<xref ref-type="table" rid="table4-0884533611436115">Table 4</xref>). Both postoperative serum levels of AST and ALT were elevated to above normal on day 6, but the rest of the data were normal. It was not necessary to stop PN during the study.</p>
<table-wrap id="table4-0884533611436115" position="float">
<label>Table 4.</label>
<caption>
<p>Various Serum Levels of Inflammation-Related Cytokines of the Study Groups Before and After Surgery</p>
</caption>
<graphic alternate-form-of="table4-0884533611436115" xlink:href="10.1177_0884533611436115-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Day 0</th>
<th align="center">Day 6</th>
<th align="center">P Value<sup><xref ref-type="table-fn" rid="table-fn6-0884533611436115">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-1β, pg/mL</td>
<td/>
<td/>
<td>.866</td>
</tr>
<tr>
<td> Composite IVFE</td>
<td>0.63 ± 0.75</td>
<td>2.22 ± 4.76</td>
<td/>
</tr>
<tr>
<td> LCT/MCT IVFE</td>
<td>0.40 ± 0.45</td>
<td>2.5 ± 5.35</td>
<td/>
</tr>
<tr>
<td>IL-6, pg/mL</td>
<td/>
<td/>
<td>.214</td>
</tr>
<tr>
<td> Composite IVFE</td>
<td>13.54 ± 3.39</td>
<td>11.53 ± 3.79</td>
<td/>
</tr>
<tr>
<td> LCT/MCT IVFE</td>
<td>13.19 ± 2.88</td>
<td>9.90 ± 4.03</td>
<td/>
</tr>
<tr>
<td>TNF-α, pg/mL</td>
<td/>
<td/>
<td>.164</td>
</tr>
<tr>
<td> Composite IVFE</td>
<td>1.86 ± 1.34</td>
<td>2.30 ± 0.79</td>
<td/>
</tr>
<tr>
<td> LCT/MCT IVFE</td>
<td>3.00 ± 2.83</td>
<td>3.89 ± 4.30</td>
<td/>
</tr>
<tr>
<td>CRP, mg/dL</td>
<td/>
<td/>
<td>.123</td>
</tr>
<tr>
<td> Composite IVFE</td>
<td>10.8 ± 28.2</td>
<td>68.8 ± 46.4</td>
<td/>
</tr>
<tr>
<td> LCT/MCT IVFE</td>
<td>13.7 ± 28.9</td>
<td>42.6 ± 51.4</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0884533611436115">
<p>CRP, C-reactive protein; IL, interleukin; MCT, medium-chain triglycerides; TNF-α, tumor necrosis factor–α.</p>
</fn>
<fn id="table-fn6-0884533611436115">
<label>a</label>
<p>The difference between the 2 groups at postoperative time points (day 6).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Proinflammatory factors (IL-1β, IL-6, TNF-α, and CRP) were comparable in the 2 groups, but no prominent differences were observed (<xref ref-type="table" rid="table5-0884533611436115">Table 5</xref>).</p>
<table-wrap id="table5-0884533611436115" position="float">
<label>Table 5.</label>
<caption>
<p>The Biochemistry Data of the Study Groups Before and After Surgery</p>
</caption>
<graphic alternate-form-of="table5-0884533611436115" xlink:href="10.1177_0884533611436115-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Day 0</th>
<th align="center">Day 6</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn8-0884533611436115">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>White blood cells, µL</td>
<td/>
<td/>
<td>.433</td>
</tr>
<tr>
<td> Composite IVFE</td>
<td>6067.5 ± 1879.0</td>
<td>9330.0 ± 3390.0</td>
<td/>
</tr>
<tr>
<td> LCT/MCT IVFE</td>
<td>6795.0 ± 3246.3</td>
<td>8560.0 ± 2719.4</td>
<td/>
</tr>
<tr>
<td>Hemoglobin, g/dL</td>
<td/>
<td/>
<td>.847</td>
</tr>
<tr>
<td> Composite IVFE</td>
<td>11.9 ± 1.7</td>
<td>11.4 ± 1.3</td>
<td/>
</tr>
<tr>
<td> LCT/MCT IVFE</td>
<td>11.9 ± 1.7</td>
<td>11.3 ± 1.3</td>
<td/>
</tr>
<tr>
<td>Total lymphocyte count, µL</td>
<td/>
<td/>
<td>.772</td>
</tr>
<tr>
<td> Composite IVFE</td>
<td>1473.5 ± 518.1</td>
<td>1133.0 ± 484.7</td>
<td/>
</tr>
<tr>
<td> LCT/MCT IVFE</td>
<td>1530.7 ± 818.4</td>
<td>1178.9 ± 509.0</td>
<td/>
</tr>
<tr>
<td>Serum urea nitrogen, mg/dL</td>
<td/>
<td/>
<td>.123</td>
</tr>
<tr>
<td> Composite IVFE</td>
<td>11.6 ± 3.9</td>
<td>16.7 ± 5.9</td>
<td/>
</tr>
<tr>
<td> LCT/MCT IVFE</td>
<td>10.9 ± 4.4</td>
<td>14.2 ± 3.9</td>
<td/>
</tr>
<tr>
<td>Creatinine, mg/dL</td>
<td/>
<td/>
<td>.191</td>
</tr>
<tr>
<td> Composite IVFE</td>
<td>0.9 ± 0.3</td>
<td>0.7 ± 0.2</td>
<td/>
</tr>
<tr>
<td> LCT/MCT IVFE</td>
<td>0.8 ± 0.3</td>
<td>0.6 ± 0.2</td>
<td/>
</tr>
<tr>
<td>AST, IU/L</td>
<td/>
<td/>
<td>.697</td>
</tr>
<tr>
<td> Composite IVFE</td>
<td>20.7 ± 12.3</td>
<td>51.7 ± 43.6</td>
<td/>
</tr>
<tr>
<td> LCT/MCT IVFE</td>
<td>21.9 ± 10.4</td>
<td>57.0 ± 42.8</td>
<td/>
</tr>
<tr>
<td>ALT, IU/L</td>
<td/>
<td/>
<td>.858</td>
</tr>
<tr>
<td> Composite IVFE</td>
<td>60.3 ± 16.5</td>
<td>113.1 ± 112.7</td>
<td/>
</tr>
<tr>
<td> LCT/MCT IVFE</td>
<td>70.7 ± 63.6</td>
<td>106.7 ± 111.9</td>
<td/>
</tr>
<tr>
<td>Total bilirubin, mg/dL</td>
<td/>
<td/>
<td>.550</td>
</tr>
<tr>
<td> Composite IVFE</td>
<td>0.7 ± 0.3</td>
<td>0.7 ± 0.3</td>
<td/>
</tr>
<tr>
<td> LCT/MCT IVFE</td>
<td>0.8 ± 0.2</td>
<td>0.6 ± 0.4</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0884533611436115">
<p>ALT, alanine aminotransferase; AST, aspartate aminotransferase; MCT, medium-chain triglycerides.</p>
</fn>
<fn id="table-fn8-0884533611436115">
<label>a</label>
<p>The difference between the 2 groups at postoperative time points (day 6).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Three patients (7.5%; 2 in the composite IVFE group and 1 in the LCT/MCT IVFE group) experienced mild to moderate adverse events, including nausea, vomiting, and fever, but otherwise the patients tolerated the treatment well. No differences were found in the frequency and intensity of adverse events in treatment groups or in the development of complications (<xref ref-type="table" rid="table6-0884533611436115">Table 6</xref>). Indeed, the LOS was the same when composite IVFE or LCT/MCT IVFE was used (12.2 ± 6.2 vs 10.4 ± 2.7 days, <italic>P</italic> = .231).</p>
<table-wrap id="table6-0884533611436115" position="float">
<label>Table 6.</label>
<caption>
<p>Clinical Outcomes of the Study Groups</p>
</caption>
<graphic alternate-form-of="table6-0884533611436115" xlink:href="10.1177_0884533611436115-table6.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">composite IVFE (n = 20)</th>
<th align="center">LCT/MCT IVFE (n = 20)</th>
<th align="center"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOS, d</td>
<td>12.2 ± 6.2</td>
<td>10.4 ± 2.7</td>
<td>.231</td>
</tr>
<tr>
<td>Postoperative complications, No.</td>
<td/>
<td/>
<td>.687</td>
</tr>
<tr>
<td> Pneumonia</td>
<td>0</td>
<td>0</td>
<td/>
</tr>
<tr>
<td> Bacteremia</td>
<td>0</td>
<td>0</td>
<td/>
</tr>
<tr>
<td> Anastomosis leaks</td>
<td>1</td>
<td>0</td>
<td/>
</tr>
<tr>
<td> Abdominal abscess</td>
<td>2</td>
<td>1</td>
<td/>
</tr>
<tr>
<td> Postoperative ileus</td>
<td>1</td>
<td>1</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0884533611436115">
<p>LOS, length of postoperative hospital stay.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section7-0884533611436115" sec-type="discussion">
<title>Discussion</title>
<p>Surgical trauma induces a catabolic response with hypercatabolism and impaired lipid tolerance.<sup><xref ref-type="bibr" rid="bibr16-0884533611436115">16</xref>,<xref ref-type="bibr" rid="bibr21-0884533611436115">21</xref></sup> Hepatic triglyceride synthesis is related to the availability of carbohydrate and fatty acid substrates.<sup><xref ref-type="bibr" rid="bibr22-0884533611436115">22</xref></sup> As a result, patients receiving postoperative PN may present with hyperlipidemia. In this study, the postoperative levels of triglycerides were elevated in both groups; however, the increase was moderate and remained within normal ranges. The clearance of triglycerides in patients administered composite IVFE or LCT/MCT IVFE was comparable, and elimination was adequate without hypertriglyceridemia. Furthermore, the postoperative total cholesterol in the composite IVFE group decreased, although the decrease was not significant. The results suggest that the postoperative infusion of composite IVFE was associated with efficient lipid elimination without clinical hyperlipidemia.</p>
<p>Moreover, there was a significant decrease in LDL in the composite IVFE group. In the present study, the preoperative LDL levels were above optimal (100–129 mg/dL) in both treatment groups, but the postoperative LDL in the composite IVFE group decreased to optimal levels (below 100 mg/dL). Administration of ω-3 fatty acids can lower plasma very low-density lipoprotein (VLDL) and usually increases LDL in patients with type IV hyperlipidemia.<sup><xref ref-type="bibr" rid="bibr23-0884533611436115">23</xref></sup> On the other hand, ω-3 fatty acids can reduce plasma LDL concentrations in healthy people,<sup><xref ref-type="bibr" rid="bibr24-0884533611436115">24</xref><xref ref-type="bibr" rid="bibr25-0884533611436115"/><xref ref-type="bibr" rid="bibr25-0884533611436115"/>-<xref ref-type="bibr" rid="bibr27-0884533611436115">27</xref></sup> in those with primary hypercholesterolemia,<sup><xref ref-type="bibr" rid="bibr25-0884533611436115">25</xref></sup> and in primates.<sup><xref ref-type="bibr" rid="bibr28-0884533611436115">28</xref></sup> Several physiological mechanisms can be considered for such an effect. Vasandani et al<sup><xref ref-type="bibr" rid="bibr29-0884533611436115">29</xref></sup> revealed upregulated hepatic LDL transport by ω-3 fatty acids and accelerated hepatic clearance of LDL through a mechanism involving apolipoprotein (apo) E. Furthermore, hepatic synthesis and secretion of VLDL are also inhibited by ω-3 fatty acids due to enhanced intracellular apoB degradation.<sup><xref ref-type="bibr" rid="bibr30-0884533611436115">30</xref></sup> In turn, decreased numbers of VLDL particles contribute to LDL lowering.</p>
<p>The ω-3 fatty acids compete with ω-6 fatty acids in the same pathway that produces eicosanoids, which are considered anti-inflammatory, antithrombotic, and vasodilatory, whereas those derived from ω-6 fatty acids are proinflammatory and prothrombotic. In fact, clinical evidence shows anti-inflammatory and immunomodulatory effects on rheumatoid arthritis,<sup><xref ref-type="bibr" rid="bibr3-0884533611436115">3</xref>,<xref ref-type="bibr" rid="bibr7-0884533611436115">7</xref><xref ref-type="bibr" rid="bibr8-0884533611436115"/>-<xref ref-type="bibr" rid="bibr9-0884533611436115">9</xref></sup> lupus,<sup><xref ref-type="bibr" rid="bibr10-0884533611436115">10</xref>,<xref ref-type="bibr" rid="bibr11-0884533611436115">11</xref></sup> and inflammatory bowel disease,<sup><xref ref-type="bibr" rid="bibr12-0884533611436115">12</xref><xref ref-type="bibr" rid="bibr13-0884533611436115"/>-<xref ref-type="bibr" rid="bibr14-0884533611436115">14</xref></sup> which are hyperinflammatory autoimmune diseases. Several studies have demonstrated that ω-3 fatty acids modulate the immune response as determined by an improved eicosanoids profile.<sup><xref ref-type="bibr" rid="bibr17-0884533611436115">17</xref>,<xref ref-type="bibr" rid="bibr31-0884533611436115">31</xref>-<xref ref-type="bibr" rid="bibr31-0884533611436115">31</xref></sup> However, in agreement with Vega-Lopez et al,<sup><xref ref-type="bibr" rid="bibr34-0884533611436115">34</xref></sup> our results indicated that administration of ω-3 fatty acids did not influence a change in plasma proinflammatory factors, including IL-1β, IL-6, TNF-α, and CRP, or clinical outcomes in healthy people after surgery. We propose several explanations. First, the beneficial effects of ω-3 fatty acids on autoimmune diseases do not become apparent until ω-3 fatty acids are consumed for at least 12 weeks,<sup><xref ref-type="bibr" rid="bibr8-0884533611436115">8</xref>,<xref ref-type="bibr" rid="bibr9-0884533611436115">9</xref></sup> whereas we administered them over a short postoperative period. Second, the hyperinflammatory response of autoimmune diseases may contribute to the differences we observed in healthy individuals receiving elective digestive surgery, where the inflammatory response may be mild or negligible. Finally, even ω-3 fatty acid supplements may change the eicosanoids profile (eg, elevated LTB5/LTB4 ratio); therefore, the effects on downstream proinflammatory factors and eventually clinical outcomes are questionable.</p>
<p>No differences were found between the composite IVFE and LCT/MCT IVFE groups in laboratory parameters or documented adverse events. It is well known that PN may alter liver function tests after days of administration and accordingly elevate AST and ALT without a change in serum total bilirubin levels. The mechanisms underlying such abnormalities are not fully understood, although they may partially result from the lack of GI stimulation by EN. Neither serious adverse events nor deaths occurred during the study. The adverse events recorded—nausea, vomiting, and fever—were mild to moderate in both groups. Nausea and vomiting were dose related and could be overcome by adjusting the infusion rate over 18 hours. On the other hand, because the fever resolved after the IVFE was administered, it might be attributed to a hypersensitivity to components of PN.</p>
<p>In conclusion, despite being a small pilot study with some limitations, we found that composite IVFE is safe and well tolerated as a conventional LCT/MCT IVFE to provide nutrition support in the immediate postoperative period during which enteral feeding is prohibited. Although the study failed to demonstrate anti-inflammatory properties in healthy people after digestive surgery, it did demonstrate that composite IVFE decreases the serum LDL level.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: This work was supported by grants from Excellence for Cancer Research Center Grant through the funding by Department of Health, Executive Yuan, Taiwan, Republic of China (DOH101-TD-C-111-002) and the Cancer Center, Kaohsiung Medical University Hospital.</p>
</fn>
<fn fn-type="other">
<p>Cheng-Jen Ma and Li-Chu Sun made equal contributions to this work and are equally considered first authors.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0884533611436115">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morris</surname><given-names>MC</given-names></name>
<name><surname>Sacks</surname><given-names>F</given-names></name>
<name><surname>Rosner</surname><given-names>B</given-names></name>
</person-group>. <article-title>Does fish oil lower blood pressure? A meta-analysis of controlled trials</article-title>. <source>Circulation</source>. <year>1993</year>;<volume>88</volume>:<fpage>523</fpage>-<lpage>533</lpage>.</citation>
</ref>
<ref id="bibr2-0884533611436115">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Appel</surname><given-names>LJ</given-names></name>
<name><surname>Miller</surname><given-names>ER</given-names><suffix>III</suffix></name>
<name><surname>Seidler</surname><given-names>AJ</given-names></name>
<name><surname>Whelton</surname><given-names>PK</given-names></name>
</person-group>. <article-title>Does supplementation of diet with ‘fish oil’ reduce blood pressure? A meta-analysis of controlled clinical trials</article-title>. <source>Arch Intern Med</source>. <year>1993</year>;<volume>153</volume>:<fpage>1429</fpage>-<lpage>1438</lpage>.</citation>
</ref>
<ref id="bibr3-0884533611436115">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kremer</surname><given-names>JM</given-names></name>
<name><surname>Lawrence</surname><given-names>DA</given-names></name>
<name><surname>Jubiz</surname><given-names>W</given-names></name><etal/>
</person-group>. <article-title>Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis: clinical and immunologic effects</article-title>. <source>Arthritis Rheum</source>. <year>1990</year>;<volume>33</volume>:<fpage>810</fpage>-<lpage>820</lpage>.</citation>
</ref>
<ref id="bibr4-0884533611436115">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guallar</surname><given-names>E</given-names></name>
<name><surname>Aro</surname><given-names>A</given-names></name>
<name><surname>Jimenez</surname><given-names>FJ</given-names></name><etal/>
</person-group>. <article-title>Omega-3 fatty acids in adipose tissue and risk of myocardial infarction: the EURAMIC study</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>1999</year>;<volume>19</volume>:<fpage>1111</fpage>-<lpage>1118</lpage>.</citation>
</ref>
<ref id="bibr5-0884533611436115">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>von Schacky</surname><given-names>C</given-names></name>
<name><surname>Angerer</surname><given-names>P</given-names></name>
<name><surname>Kothny</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>The effect of dietary omega-3 fatty acids on coronary atherosclerosis: a randomized, double-blind, placebo-controlled trial</article-title>. <source>Ann Intern Med</source>. <year>1999</year>;<volume>130</volume>:<fpage>554</fpage>-<lpage>562</lpage>.</citation>
</ref>
<ref id="bibr6-0884533611436115">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hu</surname><given-names>FB</given-names></name>
<name><surname>Bronner</surname><given-names>L</given-names></name>
<name><surname>Willett</surname><given-names>WC</given-names></name><etal/>
</person-group>. <article-title>Fish and omega-3 fatty acid intake and risk of coronary heart disease in women</article-title>. <source>JAMA</source>. <year>2002</year>;<volume>287</volume>:<fpage>1815</fpage>-<lpage>1821</lpage>.</citation>
</ref>
<ref id="bibr7-0884533611436115">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Volker</surname><given-names>D</given-names></name>
<name><surname>Fitzgerald</surname><given-names>P</given-names></name>
<name><surname>Major</surname><given-names>G</given-names></name>
<name><surname>Garg</surname><given-names>M</given-names></name>
</person-group>. <article-title>Efficacy of fish oil concentrate in the treatment of rheumatoid arthritis</article-title>. <source>J Rheumatol</source>. <year>2000</year>;<volume>27</volume>: <fpage>2343</fpage>-<lpage>2346</lpage>.</citation>
</ref>
<ref id="bibr8-0884533611436115">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cleland</surname><given-names>LG</given-names></name>
<name><surname>French</surname><given-names>JK</given-names></name>
<name><surname>Betts</surname><given-names>WH</given-names></name><etal/>
</person-group>. <article-title>Clinical and biochemical effects of dietary fish oil supplements in rheumatoid arthritis</article-title>. <source>J Rheumatol</source>. <year>1988</year>;<volume>15</volume>:<fpage>1471</fpage>-<lpage>1475</lpage>.</citation>
</ref>
<ref id="bibr9-0884533611436115">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lau</surname><given-names>CS</given-names></name>
<name><surname>Morley</surname><given-names>KD</given-names></name>
<name><surname>Belch</surname><given-names>JJ</given-names></name>
</person-group>. <article-title>Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis—a double-blind placebo controlled study</article-title>. <source>Br J Rheumatol</source>. <year>1993</year>;<volume>32</volume>:<fpage>982</fpage>-<lpage>989</lpage>.</citation>
</ref>
<ref id="bibr10-0884533611436115">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clark</surname><given-names>WF</given-names></name>
<name><surname>Parbtani</surname><given-names>A</given-names></name>
<name><surname>Naylor</surname><given-names>CD</given-names></name><etal/>
</person-group>. <article-title>Fish oil in lupus nephritis: clinical findings and methodological implications</article-title>. <source>Kidney Int</source>. <year>1993</year>;<volume>44</volume>:<fpage>75</fpage>-<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr11-0884533611436115">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walton</surname><given-names>AJ</given-names></name>
<name><surname>Snaith</surname><given-names>ML</given-names></name>
<name><surname>Locniskar</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus</article-title>. <source>Ann Rheum Dis</source>. <year>1991</year>;<volume>50</volume>:<fpage>463</fpage>-<lpage>466</lpage>.</citation>
</ref>
<ref id="bibr12-0884533611436115">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meister</surname><given-names>D</given-names></name>
<name><surname>Ghosh</surname><given-names>S</given-names></name>
</person-group>. <article-title>Effect of fish oil enriched enteral diet on inflammatory bowel disease tissues in organ culture: differential effects on ulcerative colitis and Crohn’s disease</article-title>. <source>World J Gastroenterol</source>. <year>2005</year>;<volume>11</volume>:<fpage>7466</fpage>-<lpage>7472</lpage>.</citation>
</ref>
<ref id="bibr13-0884533611436115">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hillier</surname><given-names>K</given-names></name>
<name><surname>Jewell</surname><given-names>R</given-names></name>
<name><surname>Dorrell</surname><given-names>L</given-names></name>
<name><surname>Smith</surname><given-names>CL</given-names></name>
</person-group>. <article-title>Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease</article-title>. <source>Gut</source>. <year>1991</year>;<volume>32</volume>:<fpage>1151</fpage>-<lpage>1155</lpage>.</citation>
</ref>
<ref id="bibr14-0884533611436115">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lorenz</surname><given-names>R</given-names></name>
<name><surname>Weber</surname><given-names>PC</given-names></name>
<name><surname>Szimnau</surname><given-names>P</given-names></name><etal/>
</person-group>. <article-title>Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease—a randomized, placebo-controlled, double-blind cross-over trial</article-title>. <source>J Intern Med Suppl</source>. <year>1989</year>;<volume>731</volume>:<fpage>225</fpage>-<lpage>232</lpage>.</citation>
</ref>
<ref id="bibr15-0884533611436115">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grimm</surname><given-names>H</given-names></name>
<name><surname>Kraus</surname><given-names>A</given-names></name>
</person-group>. <article-title>Immunonutrition—supplementary amino acids and fatty acids ameliorate immune deficiency in critically ill patients</article-title>. <source>Langenbecks Arch Surg</source>. <year>2001</year>;<volume>386</volume>:<fpage>369</fpage>-<lpage>376</lpage>.</citation>
</ref>
<ref id="bibr16-0884533611436115">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
<name><surname>Simoens</surname><given-names>C</given-names></name>
<name><surname>Siderova</surname><given-names>V</given-names></name><etal/>
</person-group>. <article-title>Recent developments in fat emulsions: relevance to intensive care</article-title>. <source>Nutrition</source>. <year>1997</year>;<volume>13</volume>:<fpage>73S</fpage>-<lpage>78S</lpage>.</citation>
</ref>
<ref id="bibr17-0884533611436115">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koller</surname><given-names>M</given-names></name>
<name><surname>Senkal</surname><given-names>M</given-names></name>
<name><surname>Kemen</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Impact of omega-3 fatty acid enriched TPN on leukotriene synthesis by leukocytes after major surgery</article-title>. <source>Clin Nutr</source>. <year>2003</year>;<volume>22</volume>:<fpage>59</fpage>-<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr18-0884533611436115">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Simopoulos</surname><given-names>AP</given-names></name>
<name><surname>Leaf</surname><given-names>A</given-names></name>
<name><surname>Salem</surname><given-names>N</given-names><suffix>Jr</suffix></name>
</person-group>. <article-title>Essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids</article-title>. <source>Ann Nutr Metab</source>. <year>1999</year>;<volume>43</volume>:<fpage>127</fpage>-<lpage>130</lpage>.</citation>
</ref>
<ref id="bibr19-0884533611436115">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grimm</surname><given-names>H</given-names></name>
<name><surname>Tibell</surname><given-names>A</given-names></name>
<name><surname>Norrlind</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>Immunoregulation by parenteral lipids: impact of the n-3 to n-6 fatty acid ratio</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1994</year>;<volume>18</volume>:<fpage>417</fpage>-<lpage>421</lpage>.</citation>
</ref>
<ref id="bibr20-0884533611436115">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kinsella</surname><given-names>JE</given-names></name>
<name><surname>Broughton</surname><given-names>KS</given-names></name>
<name><surname>Whelan</surname><given-names>JW</given-names></name>
</person-group>. <article-title>Dietary unsaturated fatty acids: interactions and possible needs in relation to eicosanoid synthesis</article-title>. <source>J Nutr Biochem</source>. <year>1990</year>;<volume>1</volume>:<fpage>123</fpage>-<lpage>141</lpage>.</citation>
</ref>
<ref id="bibr21-0884533611436115">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Patino</surname><given-names>JF</given-names></name>
<name><surname>de Pimiento</surname><given-names>SE</given-names></name>
<name><surname>Vergara</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Hypocaloric support in the critically ill</article-title>. <source>World J Surg</source>. <year>1999</year>;<volume>23</volume>:<fpage>553</fpage>-<lpage>559</lpage>.</citation>
</ref>
<ref id="bibr22-0884533611436115">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wolfe</surname><given-names>BM</given-names></name>
<name><surname>Ahuja</surname><given-names>SP</given-names></name>
</person-group>. <article-title>Effects of intravenously administered fructose and glucose on splanchnic secretion of plasma triglycerides in hypertriglyceridemic men</article-title>. <source>Metabolism</source>. <year>1977</year>;<volume>26</volume>:<fpage>963</fpage>-<lpage>978</lpage>.</citation>
</ref>
<ref id="bibr23-0884533611436115">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harris</surname><given-names>WS</given-names></name>
<name><surname>Ginsberg</surname><given-names>HN</given-names></name>
<name><surname>Arunakul</surname><given-names>N</given-names></name><etal/>
</person-group>. <article-title>Safety and efficacy of Omacor in severe hypertriglyceridemia</article-title>. <source>J Cardiovasc Risk</source>. <year>1997</year>;<volume>4</volume>:<fpage>385</fpage>-<lpage>391</lpage>.</citation>
</ref>
<ref id="bibr24-0884533611436115">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Connor</surname><given-names>WE</given-names></name>
<name><surname>DeFrancesco</surname><given-names>CA</given-names></name>
<name><surname>Connor</surname><given-names>SL</given-names></name>
</person-group>. <article-title>N-3 fatty acids from fish oil: effects on plasma lipoproteins and hypertriglyceridemic patients</article-title>. <source>Ann N Y Acad Sci</source>. <year>1993</year>;<volume>683</volume>:<fpage>16</fpage>-<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr25-0884533611436115">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Illingworth</surname><given-names>DR</given-names></name>
<name><surname>Schmidt</surname><given-names>EB</given-names></name>
</person-group>. <article-title>The influence of dietary n-3 fatty acids on plasma lipids and lipoproteins</article-title>. <source>Ann N Y Acad Sci</source>. <year>1993</year>;<volume>676</volume>:<fpage>60</fpage>-<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr26-0884533611436115">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weintraub</surname><given-names>MS</given-names></name>
<name><surname>Zechner</surname><given-names>R</given-names></name>
<name><surname>Brown</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Dietary polyunsaturated fats of the W-6 and W-3 series reduce postprandial lipoprotein levels: chronic and acute effects of fat saturation on postprandial lipoprotein metabolism</article-title>. <source>J Clin Invest</source>. <year>1988</year>;<volume>82</volume>:<fpage>1884</fpage>-<lpage>1893</lpage>.</citation>
</ref>
<ref id="bibr27-0884533611436115">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Worne</surname><given-names>HE</given-names></name>
<name><surname>Smith</surname><given-names>LW</given-names></name>
</person-group>. <article-title>Effects of certain pure long chain polyunsaturated fatty acid esters on the blood lipids of man; preliminary studies on the use of polyunsaturated fatty acid in atherosclerosis</article-title>. <source>Am J Med Sci</source>. <year>1959</year>;<volume>237</volume>:<fpage>710</fpage>-<lpage>721</lpage>.</citation>
</ref>
<ref id="bibr28-0884533611436115">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parks</surname><given-names>JS</given-names></name>
<name><surname>Rudel</surname><given-names>LL</given-names></name>
</person-group>. <article-title>Effect of fish oil on atherosclerosis and lipoprotein metabolism</article-title>. <source>Atherosclerosis</source>. <year>1990</year>;<volume>84</volume>:<fpage>83</fpage>-<lpage>94</lpage>.</citation>
</ref>
<ref id="bibr29-0884533611436115">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vasandani</surname><given-names>C</given-names></name>
<name><surname>Kafrouni</surname><given-names>AI</given-names></name>
<name><surname>Caronna</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Upregulation of hepatic LDL transport by n-3 fatty acids in LDL receptor knockout mice</article-title>. <source>J Lipid Res</source>. <year>2002</year>;<volume>43</volume>:<fpage>772</fpage>-<lpage>784</lpage>.</citation>
</ref>
<ref id="bibr30-0884533611436115">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>H</given-names></name>
<name><surname>Chen</surname><given-names>X</given-names></name>
<name><surname>Fisher</surname><given-names>EA</given-names></name>
</person-group>. <article-title>N-3 fatty acids stimulate intracellular degradation of apoprotein B in rat hepatocytes</article-title>. <source>J Clin Invest</source>. <year>1993</year>;<volume>91</volume>:<fpage>1380</fpage>-<lpage>1389</lpage>.</citation>
</ref>
<ref id="bibr31-0884533611436115">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grimm</surname><given-names>H</given-names></name>
<name><surname>Mertes</surname><given-names>N</given-names></name>
<name><surname>Goeters</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title>Improved fatty acid and leukotriene pattern with a novel fat emulsion in surgical patients</article-title>. <source>Eur J Nutr</source>. <year>2006</year>;<volume>45</volume>:<fpage>55</fpage>-<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr32-0884533611436115">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wachtler</surname><given-names>P</given-names></name>
<name><surname>Konig</surname><given-names>W</given-names></name>
<name><surname>Senkal</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Influence of a total parenteral nutrition enriched with omega-3 fatty acids on leukotriene synthesis of peripheral leukocytes and systemic cytokine levels in patients with major surgery</article-title>. <source>J Trauma</source>. <year>1997</year>;<volume>42</volume>:<fpage>191</fpage>-<lpage>198</lpage>.</citation>
</ref>
<ref id="bibr33-0884533611436115">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morlion</surname><given-names>BJ</given-names></name>
<name><surname>Torwesten</surname><given-names>E</given-names></name>
<name><surname>Lessire</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>The effect of parenteral fish oil on leukocyte membrane fatty acid composition and leukotriene-synthesizing capacity in patients with postoperative trauma</article-title>. <source>Metabolism</source>. <year>1996</year>;<volume>45</volume>:<fpage>1208</fpage>-<lpage>1213</lpage>.</citation>
</ref>
<ref id="bibr34-0884533611436115">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vega-Lopez</surname><given-names>S</given-names></name>
<name><surname>Kaul</surname><given-names>N</given-names></name>
<name><surname>Devaraj</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Supplementation with omega3 polyunsaturated fatty acids and all-rac alpha-tocopherol alone and in combination failed to exert an anti-inflammatory effect in human volunteers</article-title>. <source>Metabolism</source>. <year>2004</year>;<volume>53</volume>:<fpage>236</fpage>-<lpage>240</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>